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in 1989 for a child with severe Fanconi anemia [1].
Since 1993, when the first ever unrelated CB trans-
plant (UCBT) was performed at Duke University
[2], .9000 such transplants are estimated to have
been performed worldwide [3]. The increasing use
of CB in the unrelated donor setting is partially ex-
plained by the following significant findings. UCBT
apparently offers a similar [4] or reduced risk [5] of
severe graft-versus-host disease (GVHD), permitting
a less stringent criteria for HLA matching (reviewed
in [3]).
UCBT is a life-saving form of HCT; however, it is
limited by the high incidence of opportunistic infec-
tions, most of which are viral. Opportunistic infection
(OI) is the major cause of treatment-related mortality
(TRM) during the first 6 months after UCBT, and is
caused by delays in immune reconstitution. Immune
reconstitution is a highly complex process influenced
by both graft- (eg, cell dose, histocompatibility, donor
serology) and recipient-related factors (age, previous
therapy, conditioning regimen, past infectious expo-
sures, etc.). Adaptive immunity is the cumulative effect
of a network of phenotypically distinct and highly spe-
cialized leukocyte subpopulations. Antigen-presenting
dendritic cell (DC), effector, memory, and regulatory
lymphocyte subsets are the principal players of this
network. Instructional signals from the innate immune
system shape the quality and net effect of antigen-
specific immunity.
Although attaining normal ranges of specific leu-
kocyte subsets have been used extensively, we propose
that protection from clinical infections is the best sur-
rogate marker of successful immune reconstitution.66THE HIGH INCIDENCE OF INFECTIONS AFTER
UCBT OCCURS PREDOMINANTLY WITHIN THE FIRST
3-4 MONTHS AFTER TRANSPLANT
Infection-relatedmortality (IRM) is the primary or
secondary cause of death (with or without another ma-
jor cause such as GVHD) in $50% of deaths after
UCBT, with themajority of them occurring in the first
100 days [3,6-8]. The impact of early infections is
highlighted by a report from the International Bone
Marrow Transplant Registry (IBMTR). Outcome af-
ter transplantation was analyzed between recipients
of either CB (n 5 150) or from marrow that
was from HLA-matched (n 5 367) or mismatched
for 1 HLA antigen (n 5 83) [9]. IRM within 100
days after transplantation was significantly higher
among recipients of mismatched CB than among
recipients of either HLA-matched marrow or
mismatched marrow (45%, 21%, and 24%, respec-
tively; P5 .01). However, beyond day 100, the propor-
tions of infection-related deaths were similar in the 3
groups. A multicenter study from Spain also found in-
creased occurrence of severe infections during the first
100 days after UCBT (73%) than in the BMT/PBSC
groups (50%; P 5 .02) [10]. Barker et al. [11], from
the U. of Minnesota, also documented higher cumula-
tive incidence of serious infections among children
receiving UCBT (58%) immediately posttransplant,
in contrast with recipients of unmanipulated BM
(35%, P 5 .04). However, subsequently there was
a trend toward less serious infection in the UCBT
group similar to the findings of IBMTR report [9],
suggesting that the immune deficit that seems to be
so heightened in the immediate post-UCBT period
is followed by significant improvements of immunity.
Although causal relationship can not be established di-
rectly, this period coincides with the time of thymic
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cohorts separately, patients in the T cell-depleted
(TCD) group demonstrated significantly more viral
(P \ .01), but not bacterial, infections than either
UCBT or unmodified bone marrow recipients beyond
6 months. These findings, together with the report by
the COBLT investigators [12], suggest an important
protective role for postthymic T cells infused in the
graft regardless whether they include antigen experi-
enced (marrow) or almost exclusively antigen naı¨ve
(CB) T cells.
GENERAL PRINCIPLES OF IMMUNE RECOVERY AFTER HCT
Immunoablation is an obligatory consequence of
most myeloablative preparative regimens. Although
as a whole the innate immune system appears to re-
cover rapidly, within weeks after HCT, the recovery
of functional B and T lymphocytes (adaptive immu-
nity) is far more difficult to achieve [13-15]. Following
the resolution of pancytopenia after HCT, the first
wave of T cells emerging in the lymphopenic host
are peripherally expanding T lymphocytes represent-
ing the thymic-independent pathway [16]. However,
the antigen-driven expansion of peripheral T cells
leads to a limited and skewed T cell receptor (TCR)
repertoire [16]. Several weeks/months later a second
wave of T cells emerge developing from donor-derived
common lymphocyte progenitors (CLP) as the result
of de novo thymopoiesis. In the absence of significant
GVHD this thymic-dependent pathway [14,15] is
solely responsible for a fully diverse T cell repertoire.
Interestingly, by 2 years after HCT higher TCR diver-
sity may be attained in CB recipients than in recipients
of BMT [17], indicating the existence of an efficient
thymic-dependent pathway.
UNIQUE FEATURES OF NEONATAL LYMPHOCYTES AND
DENDRITIC CELLS IN CORD BLOOD
CB contains significantly higher absolute numbers
of T, natural killer (NK), and B lymphocytes than adult
peripheral blood (PB) or even marrow [18-21]. How-
ever, most UCB T cells infused with the graft are
CD45RA1/CD62L1 ‘Recent Thymic Emigrants’
(RTE) with smaller TCRgd: and CD25
1 subsets
[20]. CB T cells have been even called immature com-
pared to bulk adult T cells because of their impaired
capacity for cytokine production [22] and diminished
lytic activity [23]. Although RTE predominate in CB
it contains some antigen-experienced T cells, most no-
tably those specific for maternal minor histocompati-
bility antigens [24]. The reduced capacity of bulk CB
mononuclear cells to secrete cytokines and lympho-
kines has been demonstrated to affect granulocyte
macrophage–colony-stimulating factor (GM-CSF),M-CSF, IL-4, IL-8, IL-12, IL-15, and IL-18 (re-
viewed in [25,26]). There is reduced expression of
NFATc2 (nuclear factor of activated T cells c2), a crit-
ical transcription factor necessary for upregulation of
these and other cytokines known to amplify T cell re-
sponses [27]. The relative cytolytic deficiency of CB T
cells is associated with absent expression of Granzymes
and Perforin [28], essential for eradicating viral patho-
gens. CD251 T cells in CB are naturally occurring
regulatory T cells [29] with potent suppressor function
as opposed to peripherally activated CD251 cells [30].
Fewer UCB T cells display HLA-DR and CCR-5 ac-
tivation markers, while the CD81/CD571/CD282
and CD81/CD45RA1/CD272 ‘‘cytotoxic,’’ along
with the ‘‘skin homing’’ CLA1 T cell subsets are ab-
sent altogether [20]. Compared with adult blood
more CB T cells progress through cell cycle and enter
apoptosis. However, unlike in adult peripheral blood
(PB) the majority of proliferating Ki-671 T cells in
UCB retain a CD45RA1/RO2, CD692, CD252,
HLA-DR2 ‘‘resting’’ phenotype [20,31]. Unlike in
adult blood, there is also significant expression of telo-
merase in CB T cells [31]. In contrast with T cells, CB
NK cells are functionally ‘‘mature’’ with comparable or
better lytic activity than their bone marrow derived
counterparts [32]. Not surprisingly, ‘‘naı¨ve’’ B lym-
phocytes are in excess in CB with an abundance of
‘‘B11’’ CD51 B cells and CD232 immature B cells
[20,33].
PLACENTAL FACTORS SHAPE THE FUNCTIONAL PROFILE
OF FETAL T CELLS AND DENDRITIC CELLS
Despite an overlapping CD45RA1/CD281/
CD271 phenotype CB T cells are fundamentally dif-
ferent from ‘‘naı¨ve’’ adult T cells mostly because they
demonstrate a relative Th2/Tc2 bias. Multiple tiers
of Th2/Tc2 biasing factors exist at the maternal-fetal
interface; IL-10 secreted by cytotrophoblasts [34], re-
duced local Tryptophan levels [35], increased proges-
terone levels [36], and other placental factors (IL-4,
PGE2) (reviewed in [37]). This immunoregulatory net-
work could be viewed as part of an evolutionary adap-
tation to permit survival and avoid rejection of the
fetus. Fas-ligand expression at thematernal-fetal inter-
face may eliminate T cells activated despite these fac-
tors above [38]. The exuberant production of IL-13
primarily by CD81 T cells [39] is in sharp contrast
with lower IFN-g production that persists even after
stimulation via CD3/CD28 signaling and exogenous
IL-2 [39]. This is a consequence of differential patterns
of methylation of the IFN-g promoter [40]. Indepen-
dently, impaired APC function of neonatal/CBDC re-
stricts the potential for optimal Th1 cell responses in
neonates because of their low IL-12 expression [41-
43]. Despite these limits there is evidence that intra-
uterine viral infections, for example, cytomegalovirus
68 P. Szabolcs and D. Niedzwiecki(CMV) could generate partial Th1 immune responses
[37], although persistent and selective deficiency of an-
tiviral Th1 CD41 T cell is documented into early
childhood [44].
PREVIOUSLY REPORTED FEATURES OF IMMUNE
RECOVERY AFTER UCBT
Although mitogenic proliferative responses may
already reach normal range in children 6-9 months af-
ter UCBT, T cell reconstitution is gradual and typi-
cally does not reach age appropriate numbers before
9 months. Meanwhile, T cell recovery in adults typi-
cally extends beyond the first year, presumably related
to the inferior output of TREC1 naı¨ve T cells in older
recipients [45]. Notably, NK cell recovery is prompt
both in numbers and function in both adults and chil-
dren by the first 2 months similar to recipients of bone
marrow [46,47]. Significant B lymphocyte recovery
starts 3-4 months after transplant that may reach
normal numbers by 6-9 months [48].
Although the incidence of life-threatening viral in-
fections is high in the first 6 months after UCBT, sug-
gesting deficits in T cell numbers or function, when
monitored beyond 9 months posttransplant the speed
of T cell recovery seems to be at least comparable
[49] to or even better than that seen after unrelated
BMT [21,46,50]. Investigators from the Cord Blood
Transplantation Study (COBLT) analyzed antigen-
specific proliferation after UCBT [12]. Children with
malignancies were longitudinally tested over the first
3 years posttransplant for herpes virus specific re-
sponses (HSV, VZV, CMV). Approximately 43% of
the patients studied eventually developed a positive
T-lymphocyte proliferative response to at least 1 her-
pes virus at some point over the 3 year observational
period. In a few, proliferative responses developed as
early as within the first 30-50 days, indicating that na-
ive T lymphocytes transferred in the graft can give rise
to antigen-specific T-lymphocyte immunity before
thymic recovery [12]. Significantly, patients with a pro-
liferative response at any time in the first 3 years to any
of the herpesviruses had a lower probability of leuke-
mia relapse and a higher overall survival (OS) [12].
One may speculate that the superior proliferative T
cell response represents a powerful surrogate marker
for functional immune reconstitution leading to
more effective graft-versus-leukemia (GVL) activity.
However, the development and kinetics of protective
antigen-specific function was not evaluable [51].
PATIENT- AND GRAFT-SPECIFIC FACTORS PREDICT
THE RISK OF DEATH FROM OI IN THE FIRST 6 MONTHS
AFTER UCBT
Over the past 5 years we have studied the reconsti-
tution of immunity in the immediate post-UCBT pe-
riod (prior to thymic recovery) in .150 pediatricrecipients of single-unit UCB at Duke University to
identify surrogate immune markers for those at risk
for OI.
Several graft- and patient-specific variables were
also identified as significant factors when the labora-
tory measurements of DC and T cell reconstitution
were analyzed. To determine the impact of patient
and graft-specific factors on 6-month post-UCBT
OI-related mortality, we reviewed all consecutive pe-
diatric UCB recipients transplanted at Duke Univer-
sity Medical Center between June 1999 and October
2005 to overlap with the immune monitoring studies
[52]. Three hundred thirty pediatric recipients of sin-
gle UCB grafts were identified. Those receiving a sec-
ond transplant for primary graft failure were excluded.
Two hundred twenty of the 330 patients (67%) were
alive at 6 months (Figure 1). Of those who died by 6
months, (58%) were identified with OI (viral, fungal,
protozoal infections) implicated as a cause of death
(Figure 1). Those who died prior to 6 months and
for whom OI was not implicated as a cause of death
were omitted from the study dataset, resulting in 284
patients. Of these 284 patients, 220 patients (77%)
were alive at 6 months and 64 (23%) died at or before
6 months with cause of death related to OI. Twenty-
two patients died related to adenovirus infection and
12 because of CMV infection, rendering these 2 vi-
ruses the cause in .50% of all OI related deaths.
A logistic regression model was used to investigate
the impact of 10 demographic and clinical characteris-
tics (sex, race, age at UCBT, CMV serology, HLA
mismatches, malignancy, total body irradiation
(TBI), total graft cell dose/kg, CD31 graft cell dose/
kg, and CD31graft cell dose/kg) on the risk of death
because of OI by 6 months post UCBT. A 3-level cat-
egoric variable was also created from the 2 variables,
Figure 1. Kaplan-Meier curve of survival (months) after UCBT in
330 consecutive patients. Death related to OI is the major cause of
failure, most occurring by 6 months. Reproduced with permission
from Cytotherapy 2007, Informa Healthcare Journals.
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UCBT (nonmalignant condition treated with chemo-
therapy alone; malignancy treated with regimens in-
cluding TBI; malignancy treated without TBI).
In univariate analyses, sex (P5 .28), race (0.12) and
TBI (P 5 .80) did not predict 6-month death because
of OI. Malignancy (P5 .07) was marginally associated
with a greater probability of 6-month death because of
OI. Malignancy without TBI was also associated with
a marginally higher probability of 6-month death be-
cause of OI (P5 .04). A significantly greater probabil-
ity of 6-month OI-related death was associated with
CMV positive serology (P\ .0001), greater HLAmis-
match (P 5 .006), and older age (P 5 .0009). Higher
total graft cell dose (P 5 .001), CD341 cell dose (P
5 .014), and CD31 cell dose (P 5 .014) were associ-
ated with lower probability of death because of OI at
6 months.
Because treatment with TBI was closely related to
age 2, multivariable models were fit. Model 1 in-
cluded CMV (P 5 .0004), HLA mismatch (P 5
.042), and age (P 5 .03). Model 2 included CMV
(P\ .0001), HLA mismatch (P 5 .005), and malig-
nancy without TBI (P 5 .04). Because total graft
cell dose, CD341 cell dose, and CD31 cell dose
were also highly correlated, each of these variables
was introduced into models 1 and 2 separately. Total
graft cell dose was the strongest predictor when cell
dose variables were added to models 1 (P 5 .0097)
and 2 (P 5 .004). CD341 cell dose contributed less
significantly to both models (P 5 .02). CD31 cell
dose did not significantly contribute to model 1; how-
ever, it was marginally significant in model 2 (P 5
.05). In model 1 total graft cell dose and CD341
cell dose replaced age because cell dose/kg inversely
correlates with age. The percent concordance among
these models ranged from 71% to 75%.
Thus, in the pediatric cohort, 6-month death be-
cause of OI can be predicted by the following risk fac-
tors: older age, positive CMV serology, .1 HLA
mismatch, malignancy without TBI, and lower graftcell dose (total, CD341 and CD31) [52]. In contrast,
sex, race, and TBI alone do not predict 6-month death
because of OI [52].
DENDRITIC AND T CELL SUBSETS AT DAY 150 AFTER
UCBT SERVE AS SURROGATE MARKERS OF PROTECTION
FROM OI
To identify patients who were at increased risk for
developing OI in the first 100 days a prospective cross-
sectional study has been conducted atday1 50 post-
UCBT [53], with the latest analysis extended to
111 patients. Utilizing Trucount methodology
[20,54,55] 4-color surface and intracellular (ic) FACS
was employed to accurately enumerate and character-
ize lymphocyte and DC subsets.
All patients received myeloablative conditioning
regimes (TBI/Cy, Bu/Cy, Bu/Mel, TBI/Mel) and
equine ATG at 30 mg/kg/day between day 23 and
day 21. All received identical GVHD prophylaxis
consisting of Cyclosporine A (cSa) plus steroids, slowly
tapered after day121 in the absence of$grade II acute
GVHD (aGVHD).
Various degree of cellular reconstitution is noted
for most immune cells except for the absence of
B lymphocytes.
Table 1 lists those immune parameters that remain
significant predictors for the presence of de novo de-
veloped OI. Figure 2 shows that individuals that de-
velop OI by day 1100 have a significantly reduced
probability of OS (Figure 2A) and that death because
of OI is related to Grade III/IV GVHD (Figure 2B).
Based on these data [53], and also on data not shown,
we hypothesize that the increased prevalence of
CD81 T cells expressing/secreting HLA-DR, IFN-
g, Granzymes A, B, and Perforin represent an effort
by the emerging immune system to control the infec-
tious agent. These changes accompany downregula-
tion of CD28, and CD27 expression along with
CD57 upregulation thus represent an evolution to-
ward effector phenotype and function. Along withTable 1. Continuous Variables of Immunity Associated with OI Incidence in the First 100 days
Variable
Median Value
For Patients with OI
Median Value
For Patients without OI Logistic Regression (P-Value)
Abs number CD41 T Cells
(cell number/mL)
44 137 .02 without age in model
% CD81 T cells 44 14 \.0001
% CD571/CD282/CD81 T cells 9 3 \.02
% CD251/CD31T Cells 22 40 \.016
% TCRgd T cell subset 2.3 0.97 \.017
% ‘‘activated’’ HLA-DR1 T cells 53 38 \.009
% ‘‘NKT’’ CD31/CD561 T cells 8 4 \.01
% IFN-g Secreting T cells 18 4 \.006
Measurements in the ‘‘day 1 50 study’’ group. Confounders tested: race, age, sex, weight, CMV status, HLA mismatch, malignancy, TBI,
GVHD, high-dose steroid pulse (yes, no), anti-CD25/Daclizumab pulse (yes, no), infused total cell dose/kg, CD341 cell/kg, CD31
T cell dose/kg.
70 P. Szabolcs and D. Niedzwieckithe skewing of the T cell profile, significantly fewer
CD1231 plasmacytoid/lymphoid DC circulate in
those with infection (P5 .007), demonstrating that an-
tigen-presenting cell deficiency occurs along with lym-
phocyte alterations.
TH1 AND TC1 T CELL SUBSETS MEASURED AT DAY120
AFTER UCBT, CAN PREDICT THOSE AT RISK FOR OI
With a recent study we aimed to gain insight into
the fate and maturational biology of adoptively trans-
ferred naive T cells in the lymphopenic hosts even
prior to the onset of OI to develop predictive models
for OI incidence in the first 100 days. Blood was ob-
tained at a median 18 days post-UCBT if theWBC ex-
ceeded 400/mm3. Circulating T cell subsets and DC
counts were monitored. Since our last report [56] we
have analyzed 76 patients at a median age of 62 months
with at least 12 months follow-up. Forty four patients
(58%) presented de novowithOI (.90%viral) at ame-
dian of 35 days. Both the OI1 and OI2 patient co-
horts had low but equivalent absolute WBC, CD31,
CD41 T cells, and NK lymphocytes. DC subsets
were largely undetectable. Strikingly, 40% of circu-
lating T cells were proliferating (Ki-671), regardless
of OI status, reflecting vigorous peripheral expansion
reducing the CD45RA1/CD62L1 RTE pool to
NO OI
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Figure 2. (A) Time to death from all causes in the ‘‘day 50’’ cohort by
OI status. (B) Time to death from OI by presence or absence of se-
vere GVHD. Reproduced with permission from Cytotherapy 2007,
Informa Healthcare Journals.\20% from.90% infused in the graft only 2-3 weeks
earlier [20]. Although most cells (67% 6 27%)
expressed a ‘‘memory-like’’ CD45RA2/CD45RO1
phenotype, a significant population (14 6 28%) coex-
pressed CD45RA and RO. The robust T cell expan-
sion was accompanied by upregulation of markers of
activation with a median of 66% of T cells HLA-
DR1. Interestingly, 10% of the circulating T cells
were entering apoptosis (ic activated Caspase-31), re-
gardless of OI status.
In those who developed OI, significantly higher
proportion of the circulating T cells were CD81
(40% versus 28%, P 5 .04), expressed CCR-5 (82%
versus 55%, P 5 .009), were secreting IFN-g (35%
versus 12%, P 5 .01), and acquired a CD571/
CD282 ‘‘effector CTL’’ phenotype. In patients devel-
oping OI significantly more Perforin1/CD81 T cells
circulated (48% versus 26%, P 5 .02).
In conclusion, in the immediate posttransplant
lymphopenic period extensive T cell proliferation via
peripheral expansion leads to major immunopheno-
typic alterations accompanied by a gradual loss of the
original naı¨ve phenotype. In parallel, new T cell sub-
sets emerge displaying a phenotype associated with an-
tigenic stimulation [57]. We hypothesize that in
patients who will develop OI, even clinically undetect-
able levels of virus could induce phenotypic acquisition
of Th1/Tc1 cytotoxic effector profile.
SUMMARY
There is a great need to learn more about the biol-
ogy of immune recovery after UCBT. Fundamental
gaps in knowledge remain regarding the biology and
kinetics of developing antigen-specific protective im-
munity and understanding the impact of recipient
age and immunosuppressive agents. However, there
is also realistic hope that clinical translation of new im-
munotherapy strategies could enhance immune com-
petence after UCBT either by having an impact on
the thymic-independent early period or by fostering
thymic recovery.
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